journal
MENU ▼
Read by QxMD icon Read
search

Prescrire International

journal
https://www.readbyqxmd.com/read/27486654/the-finances-of-association-mieux-prescrire-2015-prescrire-annual-report
#1
(no author information available yet)
No abstract text is available yet for this article.
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27486653/andrew-herxheimer-medicine-for-the-people
#2
(no author information available yet)
No abstract text is available yet for this article.
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27486652/patient-leaflet-for-harvoni-sofosbuvir-ledipasvir-almost-no-information-on-adverse-effects
#3
(no author information available yet)
No abstract text is available yet for this article.
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27486651/drug-packaging-in-2015-risky-industry-choices-and-lax-regulation
#4
(no author information available yet)
Prescrire examined the packaging quality of 240 drugs in 2015. No new advances were identified, but drug packaging continues to expose patients to a variety of dangers. Some past advances persist: for example, INNs are often more legible, and recent patient leaflets tend to be clearer and more informative. But these measures are not applied to all drugs, and are rarely applied retroactively to older drugs. The overall picture in 2015 is that many drugs are difficult to identify, risky or downright dangerous to prepare, or supplied with patient leaflets that fail to correctly inform patients about their medication...
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27486650/pulmonary-embolism-and-thrombolysis
#5
(no author information available yet)
A meta-analysis of studies including about 2000 patients with pulmonary embolism suggests that thrombolysis slightly reduces overall mortality at one month in patients under 65 but increases the number of major bleeding events, including intracranial haemorrhage.
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27486649/pneumococcal-conjugate-vaccine-do-not-routinely-vaccinate-adults-aged-65-years-and-older
#6
(no author information available yet)
A randomised placebo-controlled trial of 13-valent pneumococcal conjugate vaccine was conducted in about 84 500 adults aged 65 years and older, with no particular risk factors. Four years on average after vaccination, there was no reduction in either mortality or the overall incidence of community-acquired pneumonia. It was necessary to vaccinate about 1000 individuals in order to prevent one case of vaccine-type pneumococcal pneumonia during the 4-year follow-up period.
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27486648/oral-mucositis-associated-with-cancer-therapy-guide-to-first-choice-treatments
#7
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27486647/bisphosphonates-osteonecrosis-of-the-external-auditory-canal
#8
(no author information available yet)
No abstract text is available yet for this article.
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27486646/sofosbuvir-bradycardia
#9
(no author information available yet)
No abstract text is available yet for this article.
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27486645/azithromycin-pyloric-stenosis-in-neonates
#10
(no author information available yet)
No abstract text is available yet for this article.
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27486644/sympathomimetic-decongestants-during-pregnancy-risks-for-the-unborn-child
#11
(no author information available yet)
In addition to the risk of cardiovascular events and neurological disorders, sympathomimetic decongestants have teratogenic potential, albeit weak, when taken during the first trimester of pregnancy, probably through disruption of the vascular system of the embryo and the pregnant woman. In the second and third trimesters of pregnancy, the fetus is exposed to the same adverse effects as the mother.
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27486643/common-stem-astine
#12
(no author information available yet)
No abstract text is available yet for this article.
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27486642/efavirenz-in-children-minimal-evaluation
#13
(no author information available yet)
No abstract text is available yet for this article.
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27486641/apremilast-otezla-no-progress-in-plaque-psoriasis-or-psoriatic-arthritis
#14
REVIEW
(no author information available yet)
When PUVA therapy and immunosuppressants such as methotrexate are ineffective, TNF alpha antagonists are an option for patients with severe plaque psoriasis, in the absence of a better alternative. This is also the case for patients with psoriatic arthritis after failure of a "disease-modifying" antirheumatic drug. Apremilast, an oral immunosuppressant that inhibits phosphodiesterase type 4, has been authorised in the European Union for use in these settings. In patients with plaque psoriasis, oral apremilast was compared with subcutaneous etanercept, aTNF alpha antagonist, in a randomised, doubleblind, placebo-controlled trial lasting 16 weeks and involving 250 patients in whom other treatments had failed or were inappropriate...
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27486640/empagliflozin-jardiance-type-2-diabetes-no-rush-to-use-this-drug
#15
REVIEW
(no author information available yet)
* In early 2016, metformin monotherapy remains the treatment of choice for most patients with type 2 diabetes. There are several alternatives for patients in whom metformin is poorly tolerated or ineffective. However, dapagliflozin and canagiflozin have an unfavourable harm-benefit balance and should not be used to enhance the action of metformin. Empagliflozin is the third glifozin to be authorised in the European Union for the treatment of type 2 diabetes. A randomised, double-blind, placebo-controlled trial of empaglifloznin, in combination with other glucose-lowering drugs, involved 7020 patients with type 2 diabetes, an average glycated haemoglobin (HbA1c) concentration of about 8%, and a history of at least one cardiovascular event...
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27486639/the-drug-pricing-racket
#16
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27483737/andrew-herxheimer-his-life-s-work-to-be-continued
#17
Danielle Bardelay, Gilles Bardelay
No abstract text is available yet for this article.
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27280200/olmesartan-sprue-like-enteropathy
#18
(no author information available yet)
A cohort study conducted in 2014, using data from France's mandatory health insurance system, has shown a 10-fold increased risk of hospitalisation for enteropathy with olmesartan in comparison with other ARBs (sartans) or ACE inhibitors. The increased incidence of enteropathy with olmesartan compared with other ARBs or ACE inhibitors is well documented. The French drug regulatory agency, ANSM, informed healthcare professionals of these risks in 2014. Yet prescription rates for olmesartan remain high, and new cases of olmesartan-associated enteropathy continue to be reported...
May 2016: Prescrire International
https://www.readbyqxmd.com/read/27280199/ondansetron-and-pregnancy-possible-congenital-heart-defects
#19
(no author information available yet)
Two cohort studies, including more than 2500 pregnant women exposed to ondansetron in early pregnancy, have raised concerns over an increased risk of congenital heart defects.
May 2016: Prescrire International
https://www.readbyqxmd.com/read/27280198/drug-induced-hair-loss
#20
(no author information available yet)
Hair loss can have major psychological consequences. It can be due to a wide variety of causes, including hormonal disorders, dietary factors, infections, inflammation, trauma, emotional factors, and cancer. Drugs can also induce hair loss, by interacting with the hair growth cycle. Drug-induced hair loss may be immediate or delayed, sudden or gradual, and diffuse or localised. It is usually reversible after drug discontinuation. The drugs most often implicated in hair loss are anticancer agents, interferon, azole antifungals, lithium, immunosuppressants, and many other drugs belonging to a variety of pharmacological classes...
May 2016: Prescrire International
journal
journal
32073
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"